Previous 10 | Next 10 |
2023-09-30 09:15:00 ET Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical stage company that mixes healthcare with technology and artificial intelligence (AI). Its drug discovery platform, Recursion OS, is the key to making the company a success. The company uses machine learnin...
2023-09-21 10:00:00 ET Summary Recursion Pharmaceuticals' Q2 revenue rose 43% to $11.0M, boosted by Roche-Genentech partnership, but R&D expenses spiked, widening net loss to $76.7M. Strong liquidity position with $455.9M in cash, but concerning cash burn rate of $23.5M/month;...
2023-09-20 07:47:47 ET More on Exscientia and AI drug discovery Seeking Alpha’s Quant Rating on Exscientia Exscientia Is Worth The AI-Driven Speculation Exscientia gains as enrollments begin for cancer trial AI to represent 11% of healthcare budgets in...
2023-09-15 10:07:00 ET If you're a biotech investor, you've probably heard of both Recursion Pharmaceuticals (NASDAQ: RXRX) and CRISPR Therapeutics , (NASDAQ: CRSP) two of the most followed biotechs this year. Both companies could one day lead the sector thanks to their inno...
2023-09-15 08:45:00 ET The potential for artificial intelligence (AI) to be used as a tool for better drug discovery is already obvious. AI can help in patient recruitment, better trial design, predictive analytics, and data analysis. Simply put, it can help cut the time that it takes t...
2023-09-14 05:54:53 ET Summary Recursion Pharmaceuticals is a clinical-stage biotechnology company that uses AI and experimental biology to discover new treatments for diseases. The company has a technology platform called Recursion OS, which includes a collection of images, a sea...
2023-09-11 09:35:31 ET Recursion Pharmaceuticals (NASDAQ: RXRX) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence (AI) platform for drug development, it could soon mark itself as the leading competitor in ...
SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has completed the Phase 1 study for REC-3964 in healthy volunteers. The study achieved its primary objectives ...
2023-09-04 12:00:00 ET More on AI Cathie Wood's 'Big Ideas 2023' sees Artificial Intelligence as the future Artificial intelligence is a '1995 moment' for tech. That could push stocks even higher Apple CEO Tim Cook says artificial intelligence 'is a major focus of ou...
2023-08-25 05:10:00 ET Recursion Pharmaceuticals (NASDAQ: RXRX) and 23andMe (NASDAQ: ME) are both popular biotech stocks that are wooing investors with their claims about using artificial intelligence (AI) to supercharge the drug development process. But over the last three ...
News, Short Squeeze, Breakout and More Instantly...
Recursion Pharmaceuticals Inc. Company Name:
RXRX Stock Symbol:
NASDAQ Market:
Recursion Pharmaceuticals Inc. Website:
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public offering of 30,769,...